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Re: Resubmission of revised manuscript, # jc.2017-00275; "The effect of whole body vibration 
training on bone and muscle function in children with osteogenesis imperfecta."  
 
We are very grateful for the thoughtful comments by the reviewers. Please find below a point-by-
point response to their comments. 
Reviewer #1:  
Comment 1: The study under review reports the first RCT of whole body vibration training in children 
with osteogenesis imperfecta, with the aim of improving muscle function and bone strength. The 
study is well-conducted and reported, and provides important clinical information (in the form of 
rather disappointing results). In the discussion, the dischordant muscle and bone results are taken as 
possible evidence of reduced mechanosensitivity of OI bone. These arguments are missing some 
elements of the complex relationship between muscle and bone. Consideration of comments below 
from line 278-296 could help develop this line of discussion. 
Response: These elements have been incorporated, as suggested (see below). 
Comment 2: 54: also altered bone geometry 
Response: Agreed and included. Line 55. 
Comment 3: 57-58: Please provide a supporting reference for effects on bone mass. It may also 
strengthen the clinical case for this trial to discuss effects on fractures - as far as I am aware, there is 
conflicting evidence as to whether bisphosphonate treatment in OI leads to fracture reduction. 
Response: There are various references that demonstrate an increase in bone mass to BP in children. 
As per your request, we have chosen the original Glorieux paper from 1998. The evidence for 
fracture risk reduction of BP therapy has improved (Bishop, Lancet 2013) but remains indeed under 
debate (Dwan, Cochraine review 2016). We have included the latter reference, although that debate 
we feel is somewhat outside the aims of this paper.  
Comment 4: 60-69: related to the direct mechanical effects of muscle on bone, improved balance 
and mobility would also feed into fall and hence fracture risk 
Response: Thank you. This has been added (line 69). 
Comment 5: 167-169: this is true for the one-legged hopping, as identified within the cited 
reference. In the other tests, bilateral deficit and the lack of a high-speed eccentric muscular action 
mean that peak single-limb forces will be far smaller than in hopping. 
Point-by-Point Rebuttal
Response: The reviewer is correct, the peak force from the one-legged hopping is the only 
parameter shown to be related to the muscle bone unit. This has been specified now (line 169). As 
already mentioned, the most appropriate outcomes for the single two legged jump is height and 
peak power, and for chair/heel rising tests it is also peak power. 
Comment 6: 171-175: has reproducibility of these measures been assessed? 
Response: Whilst reproducibility of single two-legged jumping, multiple one-legged hopping and 
chair/heel rising is established (Ref 41), there is no published evidence for reproducibility of balance 
testing. Reproducibility of balance tests was not tested in this study. We have now specified that we 
have followed the manufacturer’s instructions (line 173).  
Comment 7: 244-247: the purpose of this figure isn't clear, as body mass wasn't an outcome of 
interest. Would lean and potentially fat mass be more relevant? 
Response: It is correct that body mass was not a primary outcome of this study. Nevertheless, 
explorative analysis of baseline cohort characteristics highlighted the association of body mass with 
mobility and dynamic muscle function, and in the overall context of best management of children 
with OI, the impact that overweight has on mobility and muscle performance in OI was considered 
relevant and hence this figure was included.  Following your request, we have now included 
information on body composition determined by DXA, specifically lean mass /height Z-score and 
percent body fat (methods, line 128). Lean mass/height Z-score was not related to CHAQ, 6MWD or 
dynamic muscle function. However, just like BMI-Z-score, percent body fat had very similar 
relationships to CHAQ (rho=0.350, p=0.094), 6MWD (age Z-score: rho=-0.517, p=0.010; height Z-
score: rho=-0.499, p=0.013) and S2LJ (power: rho=-0.561, p=0.007; velocity: rho=-0.679, p=0.001; 
jumping height: rho=-0.560, p=0.007). These data corroborate the relevance of overweight on 
muscle performance in OI children. This information is now included (line 249-251). 
Comment 8: 278-290: this is an important point, and should be considered throughout following 
discussion of muscle-bone and mechanosensitivity. Muscle CSA increase is only a surrogate for 
muscle force increases, as neural or other size-independent factors will affect muscular output. This 
is supported by the absence of increases in muscle function. 
Response: Thank you. 
Comment 9: 290-292: it is hard to justify this conclusion given the information above. It is not 
possible to assess the mechanical loading of the bone during the study period, however the absence 
of an intervention effect on peak force suggests that the peak forces the bone experienced did not 
vary between groups. 
Response: The mechanical loading of bone during WBV should be undisputed. Yes, theoretically it is 
possible that habitual peak forces did not vary between groups during the whole study period, since 
all subjects were at least partially mobile. However, peak forces from WBV are the most logical 
explanation for higher increase in lean mass (now also confirmed by LBM/height Z-score) in the WBV 
compared to the control group. On that basis, we would suggest that it is reasonable to conclude 
that the WBV-induced increase in lean mass (=muscle) was either not translated into bone strain due 
to OI muscle producing less peak force than normal muscle (Ref 2), or bone adaptation to strain in OI 
bone is very slow.  
Comment 10: 292-293: how is the link between muscle weakness, WBV and fracture incidence 
made? It seems more likely that this is a consequence of poor mobility and falls risk. 
Response: One would certainly consider muscle weakness (‘WBV efficacy concern’) the most likely 
reason for their incident fractures, but we cannot exclude a potential WBV safety concern. There 
were also weak subjects in the control group who had no fractures. Also, atraumatic pelvic fractures 
are not commonly seen in children with OI.  Potentially, the vertical forces used during WBV may 
have been too high for the bones of the weakest OI subjects, also taking into account that these 
individuals may have delayed repair of pre-existing microfractures. We have slightly reworded this 
sentence (line 296-97). 
Comment 11: 295-296: these secondary effects are dependent on the muscle applying force to the 
bone. Even in the case of increased measured peak forces, changes in stimulus to the bone would 
only result from altered physical activity (particularly high-impact activity known to be osteogenic - 
see work from Tobias and colleagues). It would be useful to examine changes in physical activity 
patterns (ideally by accelerometry) in future studies. 
Response: Effects on bone are indeed dependent on the peak forces produced by muscle, which we 
have specified now (line 299). WBV induces these peak forces, as demonstrated by the studies in CP 
patients; in particular rotational WBV produces forces comparable to high-impact activities (see 
Fratini et al, PLoS One 2016). We agree that accelerometry should accompany future studies.  
Comment 12: 308-309: Higher density bone at the material level will still deform more than low 
density bone if total mass and/or bending/torsional strength indices are lower. 
Response: Not necessarily. Like chalk, dense OI bone breaks easily on little deformation, because it 
has both increased mineralisation density and increased molecular cross-linking, resulting in 
brittleness. In contrast, the less mineralised bones in children with rickets withstand more 
deformation without breaking that easily (hence bowing deformities develop). 
Comment 13: 331-334: related to an earlier point, are effects of WBV more effective in those 
pediatric groups with more limited mobility (such as the earlier OI WBV trial by Schoenau and 
colleagues)? 
Response: Possibly, at least in CP children with normal bone formation capacity, as already pointed 
out in lines 303-304. The OI papers from Cologne have used WBV within an intensive rehabilitation 
program that involved intensive exercise (gym work) and physiotherapy, not WBV in isolation; these 
studies suffer from the lack of a control group. To date, no WBV RCT has ever been done in OI. These 
points have already been made in the discussion and introduction. 
Comment 14: Table 1: Whilst P value was >0.05, there is a substantial difference in mean age 
between the control and intervention groups. Given mid-childhood and pubertal peaks in bone and 
body mass growth velocities (Ruff 2003, Bone, 33::317-29), there should be brief discussion of how 
age differences may have affected results. 
Response: Randomisation was stratified by pubertal stage, so age was not controlled for within the 
pubertal stage groups. We point out that growth (in height) did not differ between groups (Table 2). 
Hence we do not feel this point needs additional discussion. 
 Reviewer #2: The authors present the results of an RCT investigating the effect of WBV training on 
bone and muscle outcomes in pediatric OI. The results show that lean mass increased over the study 
period, but that functional and bone outcomes did not. The analyses were relatively straight 
forward, though limited by sample size and study duration. See below for specific comments: 
Comment 1: Abstract: - Conclusion: I think this is an overstatement of the findings for the abstract 
since mechanism wasn't assessed. Would stick with the main conclusion in the manuscript that it 
appears WBV training is not an effective tool to improve bone mass in OI 
Response: All facts are clearly stated in the results section. The conclusion section should not just be 
a summary of results, but a place for reasoning and here we merely offer/suggest a result 
interpretation. Reduced effectiveness, as suggested, can only mean reduced biomechanical 
responsiveness of the whole system, even if we cannot pinpoint the exact mechanism.  
Comment 2: Manuscript body. Methods - Line 128 - "leg bone" is that supposed to be "leg lean"? 
Response: ‘Leg bone mass’ is meant, this has been spelled out now (line 130). 
Comment 3: - Did you collect labs for vitamin D, bone turnover markers, other labs relevant to bone 
accrual? 
Response: No, mainly as the matched-pair design was already a considerable recruitment hurdle, 
and addition of bloods tests would have further limited recruitment. 
Comment 4: - Do you have calcium intake data? 
Response: No. In all three centres, all OI children are advised on the importance of dietary calcium 
intake and also advised to take regular vitamin D supplementation. 
Comment 5: Results - How many participants in each group and intramedullary rods in place (and 
how many bones)? Would this be expected to alter mechanosensation? 
Response: Five patients had rods at baseline, 2 of whom were the ones with incident fractures who 
dropped out of the study, and 1 was a matched pair whose results were not included. We would not 
expect the presence of medullary rods to alter mechanotransduction. The results of the remaining 2 
rod-carrying patients were not markedly different from those without rods but of course numbers 
are too small to draw any firm conclusions. 
Comment 6: - Are you able to calculate Z-scores for lean mass from your DXA machine? 
Response: Following your request, we have now included information on lean mass/height Z-scores 
and percent body fat (Table 1, 2).  
Comment 7: - It looks like BMI increased (though not to a significant degree) more in the WBV vs 
control group. Lean mass is closely associated with fat mass and BMI. What happened to fat mass 
over the study period in the two groups? Did it go up or down? Stable or decreasing fat mass (ideally 
expressed as Z-scores) would support an effect of the intervention on lean; increasing fat mass 
would make you wonder if the changes in lean mass were confounded by weight gain - this could 
explain the dissociation between an increase in lean mass but no improvement in functional 
outcomes with the intervention… 
Response: Thank you for this comment. We have now included information on percent body fat, and 
there is no significant difference in the change in body fat between the groups. We have also 
included results for the lean mass/height Z-score which confirmed the total lean mass finding 
(results section, and Table 1&2). 
Comment 8: - Line 275-277: It is not clear why this statement is relevant - please elaborate (here or 
in discussion) 
Response: BP therapy was not stratified for within pairs. Whilst the overall number of children on BP 
therapy in each group (WBV/Controls) happened to be similar, there could theoretically have been 
unequal distribution, hence the additional analysis.  
Comment 9: Discussion - How did the adherence data in the current study compare to past pediatric 
studies where positive effects were seen? 
Response: To our best knowledge, only the study by Leonard in Crohn’s disease (Ref 52) assessed 
adherence. They used a low magnitude vertical device and the intervention had little to no effect on 
bone. 
Comment 10: - Line 340-341 references "overweight" OI participants. How many participants in the 
current study were overweight and/or obese (perhaps this can be added to table 1)? Were there 
differences in outcomes between the overweight vs non-overweight participants? Or just continuous 
relationships between BMI and outcomes… 
Response: Six children of the 24 children at baseline were overweight (as defined by BMI Z >1.33), 
and their BMI-Z relationship with functional outcomes can be seen in Figure 1. Of the 20 children 
completing the trial, two were overweight in the control group and 4 in the WBV group. Their results 
were not noticeably different from the rest of the group. The forces created during WBV training are 
involuntary, hence the weight of subjects is not directly influencing the effect of training. If anything, 
greater body weight should be amplified by muscle and create greater forces. On the other hand, 
overweight children might be expected to be more sedentary. There was no correlation between 
delta BMI Z-score and change in outcome measures. 
Comment 11: - Other limitations that should be included in the limitations section - relatively short 
follow up period that might be too short to observe changes in bone outcomes 
Response: In fact, all other studies with positive results (i.e. in CP) were conducted over 5-6 months, 
the vast majority being less intense that our study. From a practical point of view, our opinion is that 
if there is no measurable effect after 5-6 months, then the great effort and commitment required by 
the participant does not justify the intervention. 
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Abstract 29 
Context: Osteogenesis imperfecta (OI) is a bone fragility disorder associated with reduced 30 
muscle size, dynamic muscle function and mobility. 31 
Objective: To assess the effect of whole body vibration (WBV) training on bone density and 32 
geometry, muscle size and function, mobility, and balance in children with OI. 33 
Design: Randomised controlled pilot trial 34 
Setting: Tertiary paediatric research centre 35 
Participants: Twenty-four children (5-16 years) with OI types 1,4 and limited mobility 36 
(CHAQ score ≥0.13) recruited in gender- and pubertal stage-matched pairs. Incident fractures 37 
in two boys (WBV arm) led to exclusion of two prepubertal male pairs. 38 
Intervention: 5 months of WBV training (3x3min twice daily) or regular care.  39 
Main Outcome Measures: Bone and muscle variables measured by dual-energy X-ray 40 
absorptiometry (lumbar spine, hip, total body) and peripheral quantitative computed 41 
tomography (distal and proximal tibia). Mobility assessed by six-minute walk tests and 42 
CHAQ; dynamic muscle function by mechanography. 43 
Results: All participants had reduced walking distances and dynamic muscle function 44 
(p<0.001). BMI Z-score was associated with higher CHAQ scores (rho +0.552; p=0.005) and 45 
lower walking and two-leg jumping performance (rho -0.405 to -0.654, p<0.05). The WBV 46 
and control groups did not differ in the 5-month changes in bone density or geometry. Total 47 
lean mass increased more in the WBV group (+1119g [+224 to +1744]) compared to controls 48 
(+635g [-951 to +1006]), p=0.01, without improving mobility, muscle function or balance. 49 
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Conclusions: The increase in lean mass without changes in muscle function or bone mass 50 
suggests reduced biomechanical responsiveness of the muscle-bone unit in children with OI. 51 
  52 
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INTRODUCTION  53 
Osteogenesis imperfecta (OI) is an inherited bone fragility disorder with low bone mass, high 54 
bone material density and altered geometry, leading to increased fracture risk, but also to 55 
reduced muscle size, dynamic muscle function (1,2), isometric muscle force (3,4), and 56 
limited mobility (5). Intravenous bisphosphonate (BP) therapy in children with OI increases 57 
bone mass (6) by inhibiting bone resorption, but evidence of fracture reduction remains 58 
limited (7). To date, there is a complete lack of anabolic therapy to directly target the 59 
impaired bone formation and muscle function in OI.  60 
Whole body vibration (WBV) training (high frequency, low or variable magnitude, using a 61 
vibrating platform) is widely used to improve physical fitness (8,9). Several small 62 
randomised controlled trials and observational studies in children with cerebral palsy (10-17) 63 
and other paediatric disabling conditions (12,18-21) have demonstrated a beneficial effect of 64 
WBV on walking speed, muscle strength, spasticity and balance. The underlying concept of 65 
mechanical stimulation to bone is the mechanostat theory (22), which states that bone adapts 66 
its strength to mechanical forces which are mostly imposed by muscle. Accordingly, any 67 
treatment that strengthens muscle should lead to improvements in bone structure and mass, 68 
mobility, balance and risk of fall. Of note, bone formation increases significantly and in 69 
excess of bone resorption after short-term use of WBV in healthy children (23). 70 
Using WBV therapy as an adjunctive therapy in children with OI and limited mobility is 71 
therefore tempting, especially since significant improvements in cortical thickness of femora 72 
and tibiae, and higher trabecular tibial bone volume have been reported following WBV in a 73 
mouse model of OI (24). In addition, data from an uncontrolled observational study in 53 74 
children with OI treated with WBV within an intensive rehabilitation program showed 75 
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increased muscle strength and mobility (25,26). To date, there are no randomised controlled 76 
studies using WBV in children or adults with OI. 77 
This paired randomised controlled pilot trial aimed to assess the effect of 5-months of WBV 78 
training on bone mass, geometry and density, as well as muscle function and size, mobility 79 
and balance in children with OI.  80 
 81 
SUBJECTS AND METHODS 82 
Between May 2012 and May 2015, 24 children (5-16 years) with clinically mild to moderate 83 
OI (Sillence types 1,4) with limited mobility were recruited from OI specialist clinics at 84 
tertiary Children’s Hospitals in Birmingham, Sheffield and Manchester, as well as through an 85 
advertisement placed on the Brittle Bone Society website. Limited mobility was defined by a 86 
Child Health Assessment Questionnaire (CHAQ) score of ≥0.13 (27), with the minimum 87 
ability to rise from a chair. 88 
Bisphosphonate therapy increases mobility and isometric grip force during the first treatment 89 
years (28,29). In order not to confuse such secondary improvements in muscle function due 90 
to BP therapy with primary effects from WBV, children had to be either naïve to BP therapy, 91 
or had to have received BP therapy for more than 2 years (current therapy), or stopped BP 92 
therapy at least 6 months prior to enrolment (previous therapy). Children were excluded if 93 
they had experienced a lower limb fracture within 3 months of enrolment, or a recent upper 94 
limb fracture still in plaster, if they had heart or lung disease, or if on steroid therapy (oral, 95 
systemic, topical or inhaled, for more than 3 weeks in the last 12 months) or any other bone-96 
active treatment. The study design required children to be recruited in pairs matched for 97 
gender and pubertal stage group (pre-pubertal [Tanner stage 1], pubertal [Tanner stage 2-4], 98 
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post-pubertal [Tanner stage 5]). Eligible pairs of children were invited to attend the 99 
Wellcome Trust Clinical Research Facility at Birmingham Children’s Hospital (WTCRF), 100 
where informed consent was taken from the participant and their parent or guardian, and all 101 
study investigations took place. Specific history recorded included details of medication, 102 
duration, dose and frequency of previous/current BP therapy, recent medical history, fracture 103 
and rodding surgery. Pairs of children were then randomized so that one received 5 months of 104 
twice-daily vibration training (n=12) and the other regular care (n=12), using sealed 105 
envelopes. This registered trial (NCT03029312) complied with the ethical principles for 106 
medical research set by the Declaration of Helsinki and was approved by the regional ethics 107 
committee. 108 
 109 
Outcome measures 110 
The following outcome measures were taken in both groups before and following the 5 111 
months intervention. 112 
Anthropometry and incident fractures: 113 
Height and weight were measured using a Harpenden Stadiometer and electronic scales, 114 
respectively, wearing light indoor clothing. Pubertal stages were assessed according to 115 
Tanner (30), either by physical examination or through self-rating using standard graphical 116 
illustrations. Body mass index (BMI) was calculated as kg/m2. Gender- and age-specific Z-117 
scores for height, weight and BMI were calculated according to UK reference data (31,32). 118 
Location and nature of radiographically confirmed incident fractures during the study were 119 
recorded. 120 
 121 
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Dual Energy X-Ray Absorptiometry (DXA): 122 
DXA scans of the lumbar spine, hip and total body were performed on a Lunar iDXA (GE, 123 
Madison, Wisconsin, USA). Size-corrections included calculation of bone mineral apparent 124 
density (BMAD) at the lumbar spine (33) and removing the head from the total body scan 125 
(TBLH) (34). Hip scans are reported for the right, or non-rodded, femoral neck and hip. Bone 126 
density results are presented as Z-scores for age. Lumbar spine Z-scores were generated from 127 
our large local cohort of 1500 healthy children (35). Hip and TBLH Z-scores, lean mass for 128 
height Z-scores and percent body fat were derived from the manufacturer’s database. Leg 129 
bone mass and leg lean mass were derived from the total body scan. 130 
 131 
Peripheral QCT tibia (pQCT): 132 
A pQCT scan of the tibia using a Stratec XCT2000 scanner (Stratec Medizintechnik, 133 
Pforzheim, Germany) was performed at the distal (4% of tibia length) and proximal tibia 134 
(66% of tibia length). Outcome measures included trabecular and total bone densities at the 135 
4% site, and cortical density, bone and muscle cross sectional areas, muscle density and 136 
estimated cortical thickness at the 66% site. Reproducibility of tibia bone and muscle pQCT 137 
parameters has been described previously (36,37). 138 
 139 
Mobility, Muscle function and Balance: 140 
Childhood Health Assessment Questionnaire (CHAQ): 141 
The CHAQ score is a common tool to measure mobility/disability in children, assessing 142 
various motor function skills involved in dressing, arising, eating, walking, hygiene, reach, 143 
and grip (27). The possible score range is 0 to 3, with limited mobility defined as a score 144 
≥0.13. Pain was assessed separately using a faces pain scale (38). 145 
8 
 
Six-minute walk test (6MWT):  146 
The 6MWT is a standardized endurance test where children are asked to walk as far as 147 
possible over six minutes. The maximum distance covered during this 6 minute walk 148 
(6MWD) in 30 meter laps with cones at the turning points was measured, using standardized 149 
encouragement (39). Gender-specific Z-scores for age and height were calculated as 150 
previously reported (40). 151 
 152 
Mechanography: 153 
Dynamic muscle function was assessed using a Leonardo™ Mechanograph Ground Reaction 154 
Force Plate (Novotec Medical Inc, Pforzheim, Germany) (41) with proprietary software. The 155 
following tests were performed using standard procedures, with best of three repetitions 156 
retained (42,43): 1) Single two-legged jump, a vertical countermovement jump to achieve 157 
maximum jumping height; 2) multiple one-legged hopping on the dominant forefoot (like 158 
rope-skipping) to achieve maximal vertical ground reaction forces during eccentric muscle 159 
contraction; 3) chair rise test (5 sit-to-stand repetitions); and 4) heel rise test (5 bilateral heel 160 
rises with knees kept stiff) with the aim to achieve maximal speed during the upward 161 
movement. High reproducibility of all muscle force-time data reported here has been recently 162 
described (43). 163 
 164 
Outcome variables were 1) peak power per body weight (W/kg), peak force per body weight 165 
(N/kg being dimensionless), peak velocity (m/s) and jumping height (m) during eccentric 166 
muscle contraction for the single two-legged jump, 2) peak force for the multiple one-legged 167 
hop, and 3+4) mean time per repetition (sec) and peak power in the rising phase (W/kg) in the 168 
chair and heel rise tests. Peak ground reaction force per body weight measured in multiple 169 
9 
 
one-legged hopping is considered the most appropriate variable for assessing the muscle-170 
bone unit at the tibia in children, as bone is expected to adapt to the peak forces (44).  171 
 172 
This device also measures balance (swaying area), and manufacturer’s instructions were 173 
followed. Depending on their individual ability, participants were asked to stand for ten 174 
seconds, 1) on one foot, 2) on two feet in tandem stand, 3) in semi-tandem stand and 4) in 175 
parallel feet stand. Categories 1-4 reflect decreasing balance abilities. Both decreasing 176 
balance category, and decreasing swaying area, reflect improvement. 177 
 178 
Intervention 179 
Children randomised to ‘regular care’ (controls) continued to receive routine care including 180 
physiotherapy. Children randomised to ‘vibration’ had their first WBV training sessions 181 
under supervision in the WTCRF and were subsequently supplied with a vibration device 182 
(Galileo M™, Novotec Medical, Pforzheim, Germany) for home use. Vibration training was 183 
supervised by a research physiotherapist (JS) and included several scheduled home visits to 184 
ensure correct, individualised training and adherence. Children were asked to keep a training 185 
record, and the device recorded adherence data (date, time, frequency, and duration of use). 186 
The Galileo M™ device has a motorized board that produces side-to-side alternating vertical 187 
sinusoidal (rotational) vibrations around a fulcrum in the mid-section of the plate. The 188 
vibration frequency can be selected by the user who stands on the board with both feet, 189 
wearing shoes. The peak-to-peak displacement to which the feet are exposed increases with 190 
the distance of the feet from the centre line of the vibrating board. Three positions marked 1, 191 
2 and 3 are indicated on the vibrating board, corresponding to peak-to-peak displacements of 192 
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2, 4, and 6mm. The peak acceleration exerted by vibration exercise increases with higher 193 
frequencies and higher amplitudes.  194 
Children used the device twice daily for 3 x 3 minutes, with 3 minute breaks (total active 195 
training time daily 18 min) for 5 months. Children were asked to stand upright on the 196 
platform, with knees bent (10-45 degrees, semi-squat or squat position). A schedule of 197 
increasing intensity of vibration exercise was used over time, allowing some adjustment to 198 
the patient’s physical capability. Amplitude 1 was used for the first 2 weeks, then increased 199 
to amplitude 2 and further increased up to amplitude 3, if individually possible, always using 200 
frequencies between 20-25Hz. Children were also asked to perform exercises on the platform, 201 
including shifting their weight from one side to the other or increase/decrease their knee and 202 
hip angle. Other exercise included weight shift with rotation of the trunk, and alternate 203 
flexion and extension of knees. Where possible, active squats or semi-squats were done on 204 
the platform.  205 
The safety of vertical and rotational WBV treatment regimens have been demonstrated in 206 
previous studies in children with disability (10-17) and OI (25,26). In all paediatric and adult 207 
studies, vibration treatment was well tolerated, including children with OI carrying 208 
intramedullary rods. Since forces produced during WBV therapy are lower compared to 209 
forces applied during walking and running in daily life (45-47), and participants were at least 210 
partially ambulant, WBV was not considered a safety risk. Nevertheless, children were asked 211 
to report any discomfort, fatigue or pain.  212 
Statistical Analysis 213 
In the absence of pilot data for OI children, the primary endpoint variable chosen for sample 214 
size calculation was total tibial volumetric BMD at the tibial 4% site, measured by pQCT, 215 
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guided by a pilot WBV study in disabled children, accepting their use of different vibration 216 
and scanning technology (12).  217 
Matching by gender and pubertal stage was done to optimise comparability of results. 218 
Randomization allocated one of each pair to vibration or no vibration. All outcome variables 219 
were tested for normal distribution and, given the small sample sizes, descriptive statistics are 220 
presented as median (range). To describe the extent of disease and immobility, baseline data 221 
were compared against reference data from healthy children (zero) for anthropometry 222 
(31,32), DXA (35), and dynamic muscle function (single two-leg jumps, multiple one-leg 223 
hops (42) and chair rise test (48)) using one-sample T-tests. Spearman’s correlation was used 224 
to assess associations amongst variables at baseline. 225 
Study results are reported according to the standards set by the International Society of 226 
Musculoskeletal and Neuronal Interactions (49). The 5-month change in absolute values and 227 
Z-scores in all outcome variables in the vibration group was compared with those of the 228 
control group using Wilcoxon signed rank test, or paired T-test, as appropriate. All tests were 229 
two-tailed and throughout the study p<0.05 was considered significant. Calculations were 230 
performed using SPSS Statistics for Windows, version 22.0 (IBM Corp., Armonk, NY, USA) 231 
by a qualified biostatistician (PN). 232 
 233 
RESULTS 234 
Baseline Characteristics 235 
Twenty-four children (12 pairs, matched by gender and pubertal stage) were recruited into the 236 
study. Their baseline characteristics are shown in Table 1. As expected, the total group of OI 237 
children were shorter (p<0.001) compared to the reference population (zero). The vibration 238 
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group had slightly greater BMI Z-scores and percent body fat compared to the control group. 239 
The total group’s limited mobility was demonstrated by their median (range) CHAQ score of 240 
1.187 (0.375 to 1.875) and low 6MWD Z-scores for age (-2.34 [-6.51 to -0.58]; p<0.001) and 241 
height (-1.49 [-5.60 to 0.82]; p<0.001), with no significant differences between the vibration 242 
and control groups. Similarly, dynamic muscle function variables of the total cohort were 243 
significantly lower in all patients compared to the reference population (p≤0.001), with no 244 
difference between the two groups.  245 
Figure 1 demonstrates the effect of body mass on mobility. BMI Z-score correlated 246 
positively with CHAQ scores (rho=0.552, p=0.005) and negatively with 6MWD Z-scores 247 
(rho=-0.405, p=0.049), weight-related, two-legged peak jumping power (rho=-0.557, 248 
p=0.007), velocity (rho=-0.654, p=0.001) and jumping height (rho=-0.585, p=0.004). Very 249 
similar significant relationships of these functional variables were observed with percent 250 
body fat, but not with lean mass/height Z-score (data not shown). 251 
Response to 5 months of vibration therapy 252 
Two prepubertal, male pairs had to be excluded since two boys randomised to WBV, both 253 
previously treated with BP, dropped out of the study due to incident fractures. One boy had a 254 
suspected leg fracture after consent and before starting WBV therapy which delayed the start 255 
of therapy. He later suffered an atraumatic pelvic fracture towards the end of the 5-month 256 
intervention. The other boy sustained a left fibula fracture and experienced intermittent pain 257 
in his right tibia during WBV training from a pre-existing mal-positioned rod. None of these 258 
fractures occurred during a WBV training session. In both cases, prolonged rehabilitation did 259 
not allow regular use of the device and caused an unacceptably long delay to the post-260 
intervention visits, leading to secondary exclusion. Of note, their 6MWD (age Z-scores -6.14; 261 
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-6.51) and peak two-legged jumping force (Z-scores -5.04; -5.10) at baseline were the lowest, 262 
by far, of the entire cohort with no apparent difference in bone mass. 263 
The remaining 10 pairs therefore consisted of 4 male pairs (3 prepubertal, 1 post-pubertal) 264 
and 6 female pairs (5 prepubertal, 1 postpubertal), including a pair of identical twins. Five 265 
children each in the vibration and control groups, had previous or current BP therapy for 266 
more than 2 years, and five children each were naïve to BP therapy. Median (range) 267 
adherence to WBV was 84% (63 to 96%), with recorded average frequency of 24.1Hz (23.2 268 
to 24.5), and highest amplitudes between 2 to 3. 269 
There were no significant differences between the vibration and control group in the 5-month 270 
changes in growth, bone density or geometry (Table 2). The vibration group had a 271 
significantly greater increase in total lean mass (+1119g [224 to +1744]) over 5 months 272 
compared to controls (+635g [-951 to +1006]), p=0.01, and a corresponding change in lean 273 
mass/height Z-score. Similar changes were observed in other muscle variables such as leg 274 
lean mass and cross-sectional muscle area at the 66% site, but these did not reach statistical 275 
significance (Figure 2). However, the increase in lean mass was not associated with 276 
substantive improvements in mobility or dynamic muscle function, as measured by CHAQ, 277 
6MWT and mechanography (Table 3). There was no significant difference between the two 278 
groups in variables of balance (data not shown). Adjustment for previous or current BP 279 
therapy did not alter the results. The results of the entire study population were reflected in 280 
those of the identical twin pair (both on BP therapy, data not shown).  281 
In addition to the low impact fractures that had led to exclusion of two boys, one child 282 
sustained an accidental nose fracture and another one a finger fracture in the WBV group 283 
during the study period (unrelated to WBV training sessions). There were no fractures in the 284 
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control group, apart from one child who had incidental vertebral fractures detected during the 285 
study.  286 
 287 
DISCUSSION 288 
This first randomised controlled study in children with OI demonstrated no effect of 5 289 
months, twice-daily rotational WBV on bone mass, density or geometry despite a significant 290 
increase in total lean mass. Muscle mass or size are often used as surrogates for muscle force 291 
in able-bodied children. This study in children with OI indicates that increments in lean mass 292 
are not necessarily associated with improvements in mobility, 6MWD, dynamic muscle 293 
function or balance. In line with the recent observation that children with OI produce less 294 
peak force per muscle size (2), our results suggest reduced biomechanical responsiveness of 295 
their muscle-bone unit. Together with the potential safety concern that significant incident 296 
fractures occurred in the two muscularly weakest children only in the WBV group, our results 297 
do not encourage the use of WBV in OI children. 298 
Vibration training (whether vertical or rotational) is designed to improve peak muscle forces, 299 
and secondary effects on bone are expected according to the mechanostat theory (22). The 300 
fairly large number of randomised studies demonstrating positive effects of WBV on walking 301 
speed, muscle strength, spasticity and balance in children with cerebral palsy (10-15,17) or 302 
other disabilities (12,19), indicate that this treatment modality appears efficacious and safe in 303 
children without a primary bone formation defect. Therefore, the results of this study raise 304 
several questions. 305 
Our results are in contrast with evidence from a murine model of OI, where 5 weeks of 306 
vertical WBV increased cortical thickness of femur and tibia (24), and to some extent from an 307 
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observational study in children with a wide range of OI severity which suggested rotational 308 
WBV improves motor function and walking distance (25,26). The lack of a bone effect 309 
despite improved total lean mass in this study questions whether OI bone may respond less to 310 
vibration therapy compared to non-OI bone. Such decreased responsiveness may be caused 311 
by the high material density altering the biomechanical signal (increased mechanostat set-312 
point) or by the reduced bone formation capacity typical for OI bone. Given the reduced peak 313 
force per muscle area reported in OI children (2), we speculate that the biomechanical bone 314 
strain imposed by muscle forces may possibly be translated more slowly in OI bone 315 
compared to that of able-bodied children. Whilst disease-specific bone material properties 316 
may offer an explanation for decreased biomechanical responsiveness of OI bone, the 317 
decreased responsiveness of OI muscle function to WBV therapy may also have its origin in 318 
defective collagen type I. Tendons contain plenty of collagen type I and transmit forces from 319 
muscles to bones. In OI, the biomechanical properties of tendons are impaired (50), possibly 320 
altering transmission of forces and dynamic function. Of note, reduced muscle forces and 321 
dynamic function at baseline are not just found in children with OI, but also in the OI mouse 322 
model (51).  323 
Whether and how much an individual can improve his/her muscle function in response to 324 
WBV therapy depends to some extent on the mobility and function of the individual at 325 
baseline and the intensity of training. Our cohort did not include children with severe forms 326 
of OI, in fact all were at least partially mobile by design. In their observational study of 327 
children with more severe OI, Hoyer-Kuhn et al (25) reported the effect of a rehabilitation 328 
concept including WBV, not a direct effect of WBV in isolation. In general, the forces 329 
applied during WBV are lower than during walking or running (45-47). Whilst the level of 330 
immobility in our cohort was not severe, with habitual loading forces greater than those 331 
employed during WBV, it is a fact that WBV is used as an effective fitness tool in able-332 
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bodied individuals (8). Therefore, one would still expect positive results even in our patient 333 
group with limited mobility. 334 
The intensity and duration of training in the current study (20-25Hz, 3x3min, twice daily, for 335 
5 months) was comparable with other WBV studies in children. In fact, most studies in CP 336 
used a once daily or five times/week vibration regimen, for 5-6 months. In addition, 337 
adherence to WBV was comparable with a recent larger scale WBV study in children (52). 338 
Finally, there are different brands, models, and types (vertical, rotational) of WBV devices 339 
available on the market, with variable levels of evidence supporting their effectiveness (53). 340 
This study found that higher BMI Z-score correlated with higher CHAQ score and lower 341 
6MWD, body-weight-related peak power, velocity and jumping height in the two-legged 342 
jump at baseline. Such negative associations between overweight and weight-related jumping 343 
outcomes have been previously described in able-bodied children (54). Our results indicate 344 
decreased mobility and whole-body muscle performance in overweight children with OI. 345 
Since overweight in OI is also associated with higher fracture rates (55), lifestyle 346 
modification should be an integral part of OI management (56). 347 
Limitations of this study include its small sample size. Care was taken not to include patients 348 
who had started BP therapy in the last 2 years, which is associated with secondary gains in 349 
mobility. The number of patients with previous and current BP therapy happened to be 350 
identical in both groups. Whilst we cannot completely exclude an effect, we consider it 351 
unlikely given that the 5-month changes observed in the pair of identical twins was in line 352 
with the overall study results. 353 
 354 
Conclusion 355 
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Whilst it is possible that treatment response in dynamic muscle function and bone may 356 
require longer training durations in children with OI, the effort and engagement required from 357 
the child and parents for this training is substantial. Therefore, the lack of a measurable bone 358 
effect over 5 months suggest that rotational WBV therapy is not a practical, effective 359 
treatment tool to increase bone formation and strength in OI. The incident low-impact 360 
fractures in the two weakest subjects on WBV therapy also raise concerns about safety in 361 
children with OI. Whether rotational or other forms of WBV are more efficacious in more 362 
severely immobile children with OI, or as an adjunct to an intensive rehabilitation program, 363 
requires further study. The association of overweight with impaired mobility highlights the 364 
need for active weight management in children with OI. 365 
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Acknowledgement 367 
We are indebted to patients and families for their participation in this study. We are grateful 368 
to Nicola Brown, Physiotherapist, and Claire Williams, Research Nurse, for assistance with 369 
this study. This study was funded by the Birmingham Children’s Hospital Research 370 
Foundation and the Brittle Bone Society. We also thank the Brittle Bone Society for assisting 371 
with recruitment, and Novotec Medical for technical assistance. 372 
The research was carried out at the National Institute for Health Research/Wellcome 373 
Birmingham Clinical Research Facility (Birmingham, United Kingdom). The views 374 
expressed are those of the authors and not necessarily those of the National Health Service, 375 
the National Institute for Health Research, or the Department of Health.  376 
Authors contributions: Study design: WH, PN, NS, NC; Study conduct: WH, JS, NB, PA, 377 
ZM, RP, NS, NC. Data collection: JS, WH, NC. Data analysis: PN, WH. Data interpretation: 378 
18 
 
All authors. Drafting manuscript: WH. Revising manuscript content and approving final 379 
manuscript version: All authors; WH accepts overall responsibility for data integrity. 380 
  381 
19 
 
References 382 
1. Veilleux LN, Pouliot-Laforte A, Lemay M, Cheung MS, Glorieux FH, Rauch F. The functional 383 
muscle-bone unit in patients with osteogenesis imperfecta type I. Bone 2015; 79:52-57 384 
2. Veilleux LN, Lemay M, Pouliot-Laforte A, Cheung MS, Glorieux FH, Rauch F. Muscle anatomy 385 
and dynamic muscle function in osteogenesis imperfecta type I. J Clin Endocrinol Metab 386 
2014; 99:E356-E362 387 
3. Takken T, Terlingen HC, Helders PJ, Pruijs H, Van der Ent CK, Engelbert RH. Cardiopulmonary 388 
fitness and muscle strength in patients with osteogenesis imperfecta type I. J Pediatr 2004; 389 
145:813-818 390 
4. Caudill A, Flanagan A, Hassani S, Graf A, Bajorunaite R, Harris G, Smith P. Ankle strength and 391 
functional limitations in children and adolescents with type I osteogenesis imperfecta. 392 
Pediatr Phys Ther 2010; 22:288-295 393 
5. Montpetit K, Palomo T, Glorieux FH, Fassier F, Rauch F. Multidisciplinary Treatment of 394 
Severe Osteogenesis Imperfecta: Functional Outcomes at Skeletal Maturity. Arch Phys Med 395 
Rehabil 2015; 96:1834-1839 396 
6. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of 397 
pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 1998; 339:947-398 
952 399 
7. Dwan K, Phillipi CA, Steiner RD, Basel D. Bisphosphonate therapy for osteogenesis 400 
imperfecta. Cochrane Database Syst Rev 2016; 10:CD005088 401 
8. Costantino C, Gimigliano R, Olvirri S, Gimigliano F. Whole body vibration in sport: a critical 402 
review. J Sports Med Phys Fitness 2014; 54:757-764 403 
9. Pel JJ, Bagheri J, van Dam LM, HJ vdB-E, Horemans HL, Stam HJ, van der Steen J. Platform 404 
accelerations of three different whole-body vibration devices and the transmission of 405 
vertical vibrations to the lower limbs. Med Eng Phys 2009; 31:937-944 406 
10. Katusic A, Alimovic S, Mejaski-Bosnjak V. The effect of vibration therapy on spasticity and 407 
motor function in children with cerebral palsy: a randomized controlled trial. 408 
NeuroRehabilitation 2013; 32:1-8 409 
11. Ruck J, Chabot G, Rauch F. Vibration treatment in cerebral palsy: A randomized controlled 410 
pilot study. J Musculoskelet Neuronal Interact 2010; 10:77-83 411 
12. Ward K, Alsop C, Caulton J, Rubin C, Adams J, Mughal Z. Low magnitude mechanical loading 412 
is osteogenic in children with disabling conditions. J Bone Miner Res 2004; 19:360-369 413 
13. Tupimai T, Peungsuwan P, Prasertnoo J, Yamauchi J. Effect of combining passive muscle 414 
stretching and whole body vibration on spasticity and physical performance of children and 415 
adolescents with cerebral palsy. J Phys Ther Sci 2016; 28:7-13 416 
14. Cheng HY, Yu YC, Wong AM, Tsai YS, Ju YY. Effects of an eight-week whole body vibration on 417 
lower extremity muscle tone and function in children with cerebral palsy. Res Dev Disabil 418 
2015; 38:256-261 419 
15. El-Shamy SM. Effect of whole-body vibration on muscle strength and balance in diplegic 420 
cerebral palsy: a randomized controlled trial. Am J Phys Med Rehabil 2014; 93:114-121 421 
16. Stark C, Nikopoulou-Smyrni P, Stabrey A, Semler O, Schoenau E. Effect of a new 422 
physiotherapy concept on bone mineral density, muscle force and gross motor function in 423 
children with bilateral cerebral palsy. J Musculoskelet Neuronal Interact 2010; 10:151-158 424 
17. Unger M, Jelsma J, Stark C. Effect of a trunk-targeted intervention using vibration on posture 425 
and gait in children with spastic type cerebral palsy: a randomized control trial. Dev 426 
Neurorehabil 2013; 16:79-88 427 
18. Reyes ML, Hernandez M, Holmgren LJ, Sanhueza E, Escobar RG. High-frequency, low-428 
intensity vibrations increase bone mass and muscle strength in upper limbs, improving 429 
autonomy in disabled children. J Bone Miner Res 2011; 26:1759-1766 430 
19. Eid MA. Effect of Whole-Body Vibration Training on Standing Balance and Muscle Strength in 431 
Children with Down Syndrome. Am J Phys Med Rehabil 2015; 94:633-643 432 
20 
 
20. Stark C, Hoyer-Kuhn HK, Semler O, Hoebing L, Duran I, Cremer R, Schoenau E. 433 
Neuromuscular training based on whole body vibration in children with spina bifida: a 434 
retrospective analysis of a new physiotherapy treatment program. Childs Nerv Syst 2015; 435 
31:301-309 436 
21. Rietschel E, van KS, Fricke O, Semler O, Schoenau E. Whole body vibration: a new 437 
therapeutic approach to improve muscle function in cystic fibrosis? Int J Rehabil Res 2008; 438 
31:253-256 439 
22. Frost HM. The mechanostat: a proposed pathogenic mechanism of osteoporoses and the 440 
bone mass effects of mechanical and nonmechanical agents. Bone Miner 1987; 2:73-85 441 
23. Harrison R, Ward K, Lee E, Razaghi H, Horne C, Bishop NJ. Acute bone response to whole 442 
body vibration in healthy pre-pubertal boys. J Musculoskelet Neuronal Interact 2015; 443 
15:112-122 444 
24. Vanleene M, Shefelbine SJ. Therapeutic impact of low amplitude high frequency whole body 445 
vibrations on the osteogenesis imperfecta mouse bone. Bone 2013; 53:507-514 446 
25. Hoyer-Kuhn H, Semler O, Stark C, Struebing N, Goebel O, Schoenau E. A specialized 447 
rehabilitation approach improves mobility in children with osteogenesis imperfecta. J 448 
Musculoskelet Neuronal Interact 2014; 14:445-453 449 
26. Semler O, Fricke O, Vezyroglou K, Stark C, Stabrey A, Schoenau E. Results of a prospective 450 
pilot trial on mobility after whole body vibration in children and adolescents with 451 
osteogenesis imperfecta. Clin Rehabil 2008; 22:387-394 452 
27. Dempster H, Porepa M, Young N, Feldman BM. The clinical meaning of functional outcome 453 
scores in children with juvenile arthritis. Arthritis Rheum 2001; 44:1768-1774 454 
28. Land C, Rauch F, Montpetit K, Ruck-Gibis J, Glorieux FH. Effect of intravenous pamidronate 455 
therapy on functional abilities and level of ambulation in children with osteogenesis 456 
imperfecta. J Pediatr 2006; 148:456-460 457 
29. Montpetit K, Plotkin H, Rauch F, Bilodeau N, Cloutier S, Rabzel M, Glorieux FH. Rapid 458 
increase in grip force after start of pamidronate therapy in children and adolescents with 459 
severe osteogenesis imperfecta. Pediatrics 2003; 111:e601-e603 460 
30. Tanner JM. Physical growth and development. In: Forfar JO, Arnell CC, eds. Textbook of 461 
Pediatrics. 2nd ed. Edinburgh: Churchill Livingstone; 1978:249-303. 462 
31. Freeman JV, Cole TJ, Chinn S, Jones PR, White EM, Preece MA. Cross sectional stature and 463 
weight reference curves for the UK, 1990. Arch Dis Child 1995; 73:17-24 464 
32. Cole TJ, Freeman JV, Preece MA. Body mass index reference curves for the UK, 1990. Arch 465 
Dis Child 1995; 73:25-29 466 
33. Kroger H, Vainio P, Nieminen J, Kotaniemi A. Comparison of different models for interpreting 467 
bone mineral density measurements using DXA and MRI technology. Bone 1995; 17:157-159 468 
34. Crabtree NJ, Arabi A, Bachrach LK, Fewtrell M, El-Hajj FG, Kecskemethy HH, Jaworski M, 469 
Gordon CM. Dual-energy X-ray absorptiometry interpretation and reporting in children and 470 
adolescents: the revised 2013 ISCD Pediatric Official Positions. J Clin Densitom 2014; 17:225-471 
242 472 
35. Crabtree NJ, Shaw NJ, Bishop NJ, Adams JE, Mughal MZ, Arundel P, Fewtrell MS, Ahmed SF, 473 
Treadgold LA, Högler W, Bebbington NA, Ward KA, Team AS. Amalgamated Reference Data 474 
for Size-Adjusted Bone Densitometry Measurements in 3598 Children and Young Adults-the 475 
ALPHABET Study. J Bone Miner Res 2017; 32:172-180 476 
36. Burrows M, Cooper DM, Liu D, McKay HA. Bone and muscle parameters of the tibia: 477 
agreement between the XCT 2000 and XCT 3000 instruments. J Clin Densitom 2009; 12:186-478 
194 479 
37. Sievanen H, Koskue V, Rauhio A, Kannus P, Heinonen A, Vuori I. Peripheral quantitative 480 
computed tomography in human long bones: evaluation of in vitro and in vivo precision. J 481 
Bone Miner Res 1998; 13:871-882 482 
21 
 
38. Wong DL, Baker CM. Pain in children: comparison of assessment scales. Pediatr Nurs 1988; 483 
14:9-17 484 
39. Geiger R, Strasak A, Treml B, Gasser K, Kleinsasser A, Fischer V, Geiger H, Loeckinger A, Stein 485 
JI. Six-minute walk test in children and adolescents. J Pediatr 2007; 150:395-399, 399 486 
40. Saraff V, Schneider J, Colleselli V, Ruepp M, Rauchenzauner M, Neururer S, Geiger R, Hogler 487 
W. Sex-, age-, and height-specific reference curves for the 6-min walk test in healthy children 488 
and adolescents. Eur J Pediatr 2015; 174:837-840 489 
41. Fricke O, Weidler J, Tutlewski B, Schoenau E. Mechanography--a new device for the 490 
assessment of muscle function in pediatrics. Pediatr Res 2006; 59:46-49 491 
42. Sumnik Z, Matyskova J, Hlavka Z, Durdilova L, Soucek O, Zemkova D. Reference data for 492 
jumping mechanography in healthy children and adolescents aged 6-18 years. J 493 
Musculoskelet Neuronal Interact 2013; 13:297-311 494 
43. Veilleux LN, Rauch F. Reproducibility of jumping mechanography in healthy children and 495 
adults. J Musculoskelet Neuronal Interact 2010; 10:256-266 496 
44. Anliker E, Rawer R, Boutellier U, Toigo M. Maximum ground reaction force in relation to 497 
tibial bone mass in children and adults. Med Sci Sports Exerc 2011; 43:2102-2109 498 
45. Crewther B, Cronin J, Keogh J. Gravitational forces and whole body vibration: implications for 499 
prescription of vibratory stimulation. Physical Therapy in Sport 2004; 5:37-42 500 
46. Rohlmann A, Schmidt H, Gast U, Kutzner I, Damm P, Bergmann G. In vivo measurements of 501 
the effect of whole body vibration on spinal loads. Eur Spine J 2014; 23:666-672 502 
47. Pollock RD, Woledge RC, Mills KR, Martin FC, Newham DJ. Muscle activity and acceleration 503 
during whole body vibration: effect of frequency and amplitude. Clin Biomech (Bristol, Avon) 504 
2010; 25:840-846 505 
48. Busche P, Rawer R, Rakhimi N, Lang I, Martin DD. Mechanography in childhood: references 506 
for force and power in counter movement jumps and chair rising tests. J Musculoskelet 507 
Neuronal Interact 2013; 13:213-226 508 
49. Rauch F, Sievanen H, Boonen S, Cardinale M, Degens H, Felsenberg D, Roth J, Schoenau E, 509 
Verschueren S, Rittweger J. Reporting whole-body vibration intervention studies: 510 
recommendations of the International Society of Musculoskeletal and Neuronal Interactions. 511 
J Musculoskelet Neuronal Interact 2010; 10:193-198 512 
50. Gillies AR, Lieber RL. Structure and function of the skeletal muscle extracellular matrix. 513 
Muscle Nerve 2011; 44:318-331 514 
51. Gentry BA, Ferreira JA, McCambridge AJ, Brown M, Phillips CL. Skeletal muscle weakness in 515 
osteogenesis imperfecta mice. Matrix Biol 2010; 29:638-644 516 
52. Leonard MB, Shults J, Long J, Baldassano RN, Brown JK, Hommel K, Zemel BS, Mahboubi S, 517 
Howard WK, Herskovitz R, Lee D, Rausch J, Rubin CT. Effect of Low-Magnitude Mechanical 518 
Stimuli on Bone Density and Structure in Pediatric Crohn's Disease: A Randomized Placebo-519 
Controlled Trial. J Bone Miner Res 2016; 31:1177-1188 520 
53. Rauch F. Vibration therapy. Dev Med Child Neurol 2009; 51 Suppl 4:166-168 521 
54. Rauch R, Veilleux LN, Rauch F, Bock D, Welisch E, Filler G, Robinson T, Burrill E, Norozi K. 522 
Muscle force and power in obese and overweight children. J Musculoskelet Neuronal 523 
Interact 2012; 12:80-83 524 
55. Chagas CE, Roque JP, Santarosa Emo PB, Lazaretti-Castro M, Martini LA. Do patients with 525 
osteogenesis imperfecta need individualized nutritional support? Nutrition 2012; 28:138-142 526 
56. Germain-Lee EL, Brennen FS, Stern D, Kantipuly A, Melvin P, Terkowitz MS, Shapiro JR. Cross-527 
sectional and longitudinal growth patterns in osteogenesis imperfecta: implications for 528 
clinical care. Pediatr Res 2016; 79:489-495 529 
 530 
  531 
22 
 
Figure Legends: 532 
 533 
Figure 1:  534 
Baseline correlations between BMI Z-scores of 24 children with osteogenesis imperfecta with 535 
their CHAQ score, 6-minute walk distance (Z-scores for age and height), and weight-related 536 
peak power, velocity and jumping height in the single two-legged jump (S2LJ).  537 
 538 
Figure 2  539 
A) The vibration group (white boxes) had greater increments in total lean mass over 5 months 540 
compared to pubertal stage- and gender-matched controls (grey boxes), with similar trends in 541 
leg lean mass and cross-sectional muscle area at the proximal tibia (66% site). B) There were 542 
no corresponding differences in total or leg bone mineral content (BMC) or proximal tibia 543 
cross-sectional bone area (CSA). Box-plots depict median, interquartile range and 5/95% 544 
percentiles. 545 
 546 
 547 
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Table 1: Baseline characteristics of the Study Population 
 Total group (n=24) Vibration (n=12) Control (n=12) p-value 
Age (years) 8.72 (5.03 to 16.73) 9.38 (6.59 to 16.73) 6.49 (5.03 to 16.16) 0.088 
Non-vertebral fractures last 2 years 1 (0 to 8) 1 (0 to 8) 1 (0 to 3) 0.358 
Female/Male 12/12 6/6 6/6  
Anthropometry     
  Height Z-score -0.96 (-2.73 to 0.89)*** -1.02 (-2.73 to 0.89) -0.86 (-2.50 to 0.36) 1.000 
  Weight Z-score -0.30 (-2.33 to 1.68)  0.67 (-1.59 to 1.68) -0.75 (-2.33 to 1.27) 0.057 
  BMI Z-score 0.25 (-2.43 to 2.73) 0.85 (-0.21 to 2.73) -0.15 (-2.43 to 2.38) 0.013 
Mobility     
  CHAQ score 1.187 (0.375 to 1.875) 1.187 (0.375 to 1.625) 1.187 (0.375 to 1.875) 0.907 
  Faces Pain score 20 (0 to 80) 20 (0 to 80) 25 (0 to 80) 0.573 
  6 MWD (m) 462 (246 to 693) 456 (246 to 693) 468 (331 to 592) 0.817 
  6 MWD age Z-score -2.34 (-6.51 to -0.58) *** -3.30 (-6.51 to -0.58) -1.90 (-2.94 to -0.79) 0.204 
  6 MWD height Z-score -1.49 (-5.60 to 0.82) *** -2.41 (-5.60 to 0.54) -0.90 (-2.46 to 0.82) 0.184 
DXA     
  Lumbar spine BMD Z-score -0.25 (-3.60 to 2.60) 0.00 (-2.40 to 2.60) -0.35 (-3.60 to 2.20) 0.193 
  Lumbar spine BMAD Z-score 0.50 (-3.50 to 4.80) 0.90 (-2.40 to 4.80) -0.05 (-3.50 to 4.20) 0.236 
  Femoral neck BMD Z-score (R) -1.35 (-3.70 to 1.50)*** -2.10 (-3.70 to 1.50) -1.10 (-3.60 to 0.50) 0.948 
  Hip BMD Z-score (R) -1.45 (-4.30 to 1.30)** -1.70 (-4.30 to 1.30) -1.40 (-3.20 to 1.20) 0.870 
  TBLH BMD Z-score -0.75 (-2.90 to 1.60)*** -0.75 (-2.90 to 0.10) -0.85 (-2.60 to 1.60) 0.908 
  Lean Mass/Height Z-score -0.36 (-2.33 to 1.64) -0.26 (-1.13 to 1.48) -0.36 (-2.33 to 1.64) 0.425 
  Percent body fat (%) 32.3 (21.7 to 50.8) 37.2 (24.6 to 50.8) 30.2 (21.7 to 39.4) 0.019 
Single Two-Leg Jump     
  Peak power Z-score -2.17 (-10.90 to -0.49)*** -3.10 (-10.90 to -0.57) -1.71 (-2.89 to -0.49) 0.128 
  Peak force Z-score -2.85 (-5.10 to 1.52)*** -3.40 (-5.10 to -0.35) -2.40 (-4.49 to 1.52) 0.422 
  Jumping height Z-score -2.50 (-8.50 to -0.83)*** -3.16 (-8.50 to -1.47) -2.00 (-3.41 to -0.83) 0.052 
Multiple One-Leg hop     
  Peak force Z-score -2.26 (-4.33 to -1.26)*** -2.18 (-4.33 to -1.31) -2.33 (-4.20 to -1.26) 0.875 
Chair Rise test     
  Time per repetition Z-score 1.93 (-1.30 to 8.66)*** 1.93 (0.70 to 5.57) 2.43 (-1.30 to 8.66) 0.655 
  Peak power Z-score -1.87 (-3.01 to 0.58)*** -2.09 (-3.01 to 0.39) -1.55 (-2.50 to 0.58) 0.205 
** <0.01, *** <0.001, p-value for comparison with reference values from healthy children 
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Table 2. Comparison of the Change in Growth and Bone Variables over 5 Months 
 
Change Vibration (n=10) Control (n=10) Difference* p-value 
Anthropometry 
    
  Height Z-score -0.10 (-0.58 to 0.19) -0.12 (-0.30 to 0.20) +0.02 0.982 
  Weight Z-score 0.11 (-0.08 to 0.39) -0.05 (-0.57 to 0.27) +0.16 0.104 
  BMI Z-score 0.33 (-0.24 to 0.50) 0.05 (-0.60 to 0.43) +0.28 0.171 
DXA   
 
 
  Lumbar spine BMD Z-score 0.0 (-0.5 to 0.5) -0.1 (-0.4 to 0.6) +0.1 0.918 
  Lumbar spine BMAD Z-score -0.1 (-2.1 to 0.7) -0.1 (-0.3 to 0.9) 0 0.296 
  Femoral neck BMD Z-score (R) -0.1 (-0.5 to 0.3) 0.1 (-0.8 to 0.5) -0.2 0.418 
  Hip BMD Z-score (R) 0.0 (-0.4 to 0.5) -0.1 (-0.3 to 0.2) +0.1 0.746 
  TBLH BMD Z-score 0.1 (-0.2 to 0.3) -0.1 (-0.4 to 0.7) +0.2 0.280 
  Lean Mass/Height Z-score 0.09 (-0.56 to 0.42) -0.07 (-0.47 to 0.27) +0.16 0.038 
  Percent body fat (%) 1.7 (-0.7 to 3.1) 2.3 (-2.0 to 3.7) -0.6 0.948 
pQCT distal tibia (4%)    
 
 
  Total BMD (mg/cm3) 3.0 (-4.2 to 46.4) 5.4 (-38.9 to 42.6) -2.4 0.634 
  Trabecular BMD (g/cm3) 5.6 (-47.1 to 78.5) -10.7 (-34.4 to 94.4) +16.3 0.508 
pQCT proximal tibia (66%)   
 
 
  Cortical BMD (mg/cm3) 4.2 (-26.4 to 30.3) 8.8 (-27.4 to 115.2) -4.6 0.805 
  Cortical area (mm2) 8.3 (-10.5 to 17.6) 9.3 (-4.5 to 30.5) -1 0.508 
  Cortical thickness (mm) 0.18 (-0.31 to 0.44) 0.20 (-0.20 to 0.92) -0.02 0.445 
  Bone/muscle ratio -0.03 (-0.35 to 0.52) 0.19 (-0.54 to 2.64) -0.22 0.277 
  Muscle Density (g/cm3) 0.54 (-2.26 to 3.94) 0.35 (-1.03 to 4.56) +0.19 0.586 
*Mean numerical difference of changes of the vibration group relative to the control group 
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Table 3. Comparison of the Change in Muscle Function and Mobility over 5 Months 
 
Change n Vibration n Control Difference* p-value 
Mobility, Pain, Endurance     
 
 
  CHAQ score 10 -0.25 (-1.00 to 0.63) 10 -0.19 (-0.63 to 0.75) -0.06 0.319 
  Faces pain score 10 5 (-30 to 40) 10 0 (-30 to 60) +5 0.933 
  6 MWD (m) 10 -17 (-83 to 122) 10 -18 (-70 to 51) +1 0.278 
  6 MWD age Z-score 10 -0.39 (-1.51 to 1.95) 10 -0.56 (-1.35 to 0.43) +0.17 0.184 
  6 MWD height Z-score 10 -0.41 (-1.41 to 1.74) 10 -0.50 (-1.20 to 0.53) +0.09 0.211 
Single Two Leg Jump     
 
 
  Peak power (W/kg) 10 0.23 (-5.98 to 7.49) 8 -0.82 (-7.26 to 6.25) +1.05 0.527 
  Peak velocity (m/s) 10 -0.01 (-0.16 to 0.57) 8 -0.12 (-0.35 to 0.31) +0.11 0.327 
  Peak force (N/kg) 10 0.03 (-1.03 to 0.50) 8 -0.08 (-0.76 to 0.34) +0.11 0.779 
  Jumping height (m) 10 0.00 (-0.04 to 0.07) 8 -0.02 (-0.08 to 0.17) +0.02 0.624 
Multiple One Leg Hop     
 
 
  Peak force (N/kg) 10 -0.06 (-0.23 to 0.14) 10 -0.09 (-0.17 to 0.50) +0.03 0.600 
Chair Rise Test     
 
 
  Time per repetition (sec) 10 -0.01 (-0.71 to 0.29) 10 -0.12 (-1.34 to 0.34) +0.11 0.240 
  Peak power (W/kg) 10 0.29 (-2.21 to 4.76) 10 0.15 (-2.44 to 4.59) +0.14 0.868 
Heel Rise Test     
 
 
  Time per repetition (sec) 10 0.02 (-0.28 to 0.32) 9 -0.08 (-0.57 to 0.45) +0.1 0.714 
  Peak power (W/kg) 10 0.58 (-2.38 to 3.53) 9 -0.50 (-4.87 to 5.52) +1.08 0.764 
*Mean numerical difference of changes of the vibration group relative to the control group 
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